Beam Therapeutics(BEAM)
$25.15-1.87 (-4.77%)
BEAM
Beam Therapeutics financials statements
$25.15
At close:-1.87 (-4.77%)
Want to see BEAM full AI Analyst Report?
Beam Therapeutics (BEAM) Ratios
2,358 Followers
Beam Therapeutics Ratios
BEAM's free cash flow for Q3 2026 was $-111.96M. For the 2026 fiscal year, BEAM's free cash flow was decreased by $-1.21M and operating cash flow was $-110.75M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.09 | 4.82 | 5.89 | 4.89 | 5.96 |
| Quick Ratio | 13.09 | 4.82 | 5.89 | 4.89 | 5.96 |
| Cash Ratio | 3.04 | 1.55 | 2.12 | 1.04 | 2.62 |
| Solvency Ratio | -0.24 | -0.96 | -0.22 | -0.45 | -0.56 |
| Operating Cash Flow Ratio | -3.56 | -1.91 | -0.73 | 0.10 | -0.31 |
| Short-Term Operating Cash Flow Coverage | -24.03 | 0.00 | 0.00 | 0.00 | -28.98 |
| Net Current Asset Value | $ 1.03B | $ 507.87M | $ 732.66M | $ 484.66M | $ 625.29M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.20 | 0.15 | 0.12 | 0.13 | 0.10 |
| Debt-to-Equity Ratio | 0.24 | 0.22 | 0.18 | 0.24 | 0.18 |
| Debt-to-Capital Ratio | 0.19 | 0.18 | 0.15 | 0.20 | 0.15 |
| Long-Term Debt-to-Capital Ratio | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.20 | 1.50 | 1.49 | 1.83 | 1.78 |
| Debt Service Coverage Ratio | -0.24 | 0.00 | 0.00 | 0.00 | -100.60 |
| Interest Coverage Ratio | -8.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.41 | 1.96 | 2.24 | 2.56 | 2.30 |
| Net Debt to EBITDA | 0.08 | 0.34 | 1.79 | 0.17 | 1.79 |
| Profitability Margins | |||||
| Gross Profit Margin | 84.05% | -478.67% | 100.00% | -411.48% | -347.75% |
| EBIT Margin | -25.95% | -593.06% | -46.73% | -555.61% | -458.13% |
| EBITDA Margin | -9.99% | -558.55% | -38.91% | -532.39% | -443.76% |
| Operating Profit Margin | -274.57% | -654.25% | -46.73% | -555.61% | -757.01% |
| Pretax Profit Margin | -57.24% | -593.06% | -34.73% | -468.94% | -714.91% |
| Net Profit Margin | -57.24% | -593.13% | -35.09% | -474.54% | -714.91% |
| Continuous Operations Profit Margin | -57.24% | -593.13% | -35.09% | -474.54% | -714.91% |
| Net Income Per EBT | 100.00% | 100.01% | 101.04% | 101.19% | 100.00% |
| EBT Per EBIT | 20.85% | 90.65% | 74.32% | 84.40% | 94.44% |
| Return on Assets (ROA) | -5.40% | -34.13% | -9.08% | -21.55% | -25.14% |
| Return on Equity (ROE) | -6.46% | -51.36% | -13.50% | -39.41% | -44.83% |
| Return on Capital Employed (ROCE) | -27.72% | -45.08% | -14.07% | -30.27% | -31.12% |
| Return on Invested Capital (ROIC) | -27.43% | -44.43% | -13.93% | -29.99% | -30.88% |
| Return on Tangible Assets | -5.40% | -34.13% | -9.08% | -21.55% | -25.14% |
| Earnings Yield | -2.92% | -18.46% | -6.31% | -10.56% | -7.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 |
| Payables Turnover | 2.18 | 94.95 | 0.00 | 34.51 | 31.06 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.68 | 0.29 | 1.59 | 0.26 | 0.28 |
| Asset Turnover | 0.09 | 0.06 | 0.26 | 0.05 | 0.04 |
| Working Capital Turnover Ratio | 0.15 | 0.07 | 0.40 | 0.06 | 0.08 |
| Cash Conversion Cycle | -167.50 | -3.84 | 0.00 | -10.58 | 2100.35 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 2112.11 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 167.50 | 3.84 | 0.00 | 10.58 | 11.75 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 2112.11 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.49 | -4.22 | -1.93 | 0.32 | -1.03 |
| Free Cash Flow Per Share | -3.64 | -4.33 | -2.37 | -0.38 | -1.76 |
| Dividend Paid and CapEx Coverage Ratio | -23.09 | -38.82 | -4.42 | 0.46 | -1.42 |
| Capital Expenditure Coverage Ratio | -23.09 | -38.82 | -4.42 | 0.46 | -1.42 |
| Operating Cash Flow Coverage Ratio | -1.17 | -2.15 | -0.86 | 0.13 | -0.45 |
| Operating Cash Flow to Sales Ratio | -2.47 | -5.47 | -0.39 | 0.37 | -1.28 |
| Free Cash Flow Yield | -13.13% | -17.45% | -8.71% | -0.96% | -2.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -34.22 | -5.41 | -15.85 | -9.47 | -13.81 |
| Price-to-Sales (P/S) Ratio | 19.62 | 32.14 | 5.56 | 44.95 | 98.73 |
| Price-to-Book (P/B) Ratio | 2.21 | 2.78 | 2.14 | 3.73 | 6.19 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.61 | -5.73 | -11.48 | -103.63 | -45.26 |
| Price-to-Operating Cash Flow Ratio | -7.94 | -5.88 | -14.08 | 121.56 | -77.24 |
| Price-to-Earnings Growth (PEG) Ratio | 0.42 | -0.03 | 0.27 | 0.33 | -2.71 |
| Enterprise Value Multiple | -196.25 | -5.41 | -12.50 | -8.28 | -20.46 |
| Enterprise Value | 2.74B | 1.92B | 1.84B | 2.68B | 4.71B |
| EV to EBITDA | -196.25 | -5.41 | -12.50 | -8.28 | -20.46 |
| EV to Sales | 19.61 | 30.24 | 4.86 | 44.07 | 90.77 |
| EV to Free Cash Flow | -7.61 | -5.39 | -10.04 | -101.59 | -41.62 |
| EV to Operating Cash Flow | -7.94 | -5.53 | -12.31 | 119.17 | -71.01 |
| Tangible Book Value Per Share | 12.52 | 8.91 | 12.72 | 10.48 | 12.87 |
| Shareholders’ Equity Per Share | 12.52 | 8.91 | 12.72 | 10.48 | 12.87 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.01 | -0.01 | 0.00 |
| Revenue Per Share | 1.41 | 0.77 | 4.90 | 0.87 | 0.81 |
| Net Income Per Share | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 |
| Tax Burden | 1.00 | 1.00 | 1.01 | 1.01 | 1.00 |
| Interest Burden | 2.21 | 1.00 | 0.74 | 0.84 | 1.56 |
| Research & Development to Revenue | 2.93 | 5.79 | 1.16 | 5.11 | 7.47 |
| SG&A to Revenue | 0.81 | 1.76 | 0.31 | 1.44 | 1.10 |
| Stock-Based Compensation to Revenue | 0.67 | 1.90 | 0.26 | 1.38 | 0.84 |
| Income Quality | 4.31 | 0.92 | 1.13 | -0.08 | 0.18 |
Currency in USD
